Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 69


Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical Role.

Yuan Q, Furukawa T, Tashiro T, Okita K, Jin ZH, Aung W, Sugyo A, Nagatsu K, Endo H, Tsuji AB, Zhang MR, Masuko T, Inoue M, Fujibayashi Y, Saga T.

PLoS One. 2015 Nov 16;10(11):e0143076. doi: 10.1371/journal.pone.0143076. eCollection 2015.


Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma.

Kumai T, Ohkuri T, Nagato T, Matsuda Y, Oikawa K, Aoki N, Kimura S, Celis E, Harabuchi Y, Kobayashi H.

Sci Rep. 2015 Nov 5;5:16280. doi: 10.1038/srep16280.


Stress-response balance drives the evolution of a network module and its host genome.

González C, Ray JC, Manhart M, Adams RM, Nevozhay D, Morozov AV, Balázsi G.

Mol Syst Biol. 2015 Aug 31;11(8):827. doi: 10.15252/msb.20156185.


Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.

Mendell J, Freeman DJ, Feng W, Hettmann T, Schneider M, Blum S, Ruhe J, Bange J, Nakamaru K, Chen S, Tsuchihashi Z, von Pawel J, Copigneaux C, Beckman RA.

EBioMedicine. 2015 Feb 12;2(3):264-71. doi: 10.1016/j.ebiom.2015.02.005. eCollection 2015 Mar.


Oligoclonal antibodies to target the ErbB family.

D'Souza JW, Robinson MK.

Expert Opin Biol Ther. 2015 Jul;15(7):1015-21. doi: 10.1517/14712598.2015.1042362. Epub 2015 May 2.


Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.

Chan BA, Hughes BG.

Transl Lung Cancer Res. 2015 Feb;4(1):36-54. doi: 10.3978/j.issn.2218-6751.2014.05.01. Review.


Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.

Meneses-Lorente G, Friess T, Kolm I, Hölzlwimmer G, Bader S, Meille C, Thomas M, Bossenmaier B.

Cancer Chemother Pharmacol. 2015 Apr;75(4):837-50. doi: 10.1007/s00280-015-2697-8. Epub 2015 Feb 22.


The Potential of panHER Inhibition in Cancer.

Wang X, Batty KM, Crowe PJ, Goldstein D, Yang JL.

Front Oncol. 2015 Jan 28;5:2. doi: 10.3389/fonc.2015.00002. eCollection 2015. Review.


Ten things you should know about protein kinases: IUPHAR Review 14.

Fabbro D, Cowan-Jacob SW, Moebitz H.

Br J Pharmacol. 2015 Jun;172(11):2675-700. doi: 10.1111/bph.13096. Epub 2015 Mar 24.


Recent advances in the HER2 targeted therapy of gastric cancer.

Matsuoka T, Yashiro M.

World J Clin Cases. 2015 Jan 16;3(1):42-51. doi: 10.12998/wjcc.v3.i1.42. Review.


Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas.

Tang D, Liu CY, Shen D, Fan S, Su X, Ye P, Gavine PR, Yin X.

Onco Targets Ther. 2014 Dec 16;8:7-14. doi: 10.2147/OTT.S70922. eCollection 2015.


Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies.

D'Souza JW, Reddy S, Goldsmith LE, Shchaveleva I, Marks JD, Litwin S, Robinson MK.

PLoS One. 2014 Nov 11;9(11):e112376. doi: 10.1371/journal.pone.0112376. eCollection 2014.


Hidden treasures in "ancient" microarrays: gene-expression portrays biology and potential resistance pathways of major lung cancer subtypes and normal tissue.

Kerkentzes K, Lagani V, Tsamardinos I, Vyberg M, Røe OD.

Front Oncol. 2014 Sep 29;4:251. doi: 10.3389/fonc.2014.00251. eCollection 2014.


Integrated analysis reveals that STAT3 is central to the crosstalk between HER/ErbB receptor signaling pathways in human mammary epithelial cells.

Gong C, Zhang Y, Shankaran H, Resat H.

Mol Biosyst. 2015 Jan;11(1):146-58. doi: 10.1039/c4mb00471j. Epub 2014 Oct 15.


EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.

Lin Y, Wang X, Jin H.

Am J Cancer Res. 2014 Sep 6;4(5):411-35. eCollection 2014. Review.


Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS.

Korpanty GJ, Graham DM, Vincent MD, Leighl NB.

Front Oncol. 2014 Aug 11;4:204. doi: 10.3389/fonc.2014.00204. eCollection 2014. Review.


Novel therapeutic targets for pancreatic cancer.

Tang SC, Chen YC.

World J Gastroenterol. 2014 Aug 21;20(31):10825-44. doi: 10.3748/wjg.v20.i31.10825. Review.


Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, Drobot L, Rakus D, Gizak A, Laidler P, Dulińska-Litewka J, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Montalto G, Cervello M, Fitzgerald TL, Demidenko Z, Martelli AM, Cocco L, Steelman LS, McCubrey JA.

Oncotarget. 2014 Jul 15;5(13):4603-50. Review.


Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.

Dong Z, Meller J, Succop P, Wang J, Wikenheiser-Brokamp K, Starnes S, Lu S.

Int J Oncol. 2014 Sep;45(3):978-84. doi: 10.3892/ijo.2014.2486. Epub 2014 Jun 10.


Targeting of erbB3 receptor to overcome resistance in cancer treatment.

Ma J, Lyu H, Huang J, Liu B.

Mol Cancer. 2014 May 8;13:105. doi: 10.1186/1476-4598-13-105. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk